Efficacy and safety of tezacaftor/ ivacaftor and ivacaftor in patients aged ≥12 years with cf heterozygous for f508del and a residual function mutation: A randomized, double-blind, placebo-controlled, crossover phase 3 study

Authors
Category Primary study
ConferencePediatric Pulmonology
Year 2017
This article has no abstract
Epistemonikos ID: 3c2ed15923608743b2e1d2b49b911747038a227a
First added on: Apr 29, 2026